Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cycle 4 Consolidation-Gruppo Italiano Malattie EMatologiche dell'Adulto-acute lymphoblastic leukemia-lymphoblastic lymphoma
- Development stage
- Unknown
- Lead developer
- GIMEMA
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Intramuscular, Oral
01
Overview
Cycle 4 Consolidation refers to a specific treatment phase within the GIMEMA LAL1913 clinical trial protocol, a pediatric-inspired regimen developed for adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. This specific cycle consists of a combination of chemotherapeutic agents, including cytarabine (Ara-C), 6-mercaptopurine (6-MP), and pegaspargase (pegylated L-asparaginase). The regimen is designed by the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) to achieve early minimal residual disease (MRD) negativity. The combination works through multiple pathways: pegaspargase depletes circulating L-asparagine, an amino acid essential for leukemic cell survival; cytarabine inhibits DNA polymerase and incorporates into DNA to cause chain termination; and mercaptopurine interferes with purine biosynthesis, collectively inducing apoptosis in malignant lymphoblasts.
- Other names
- Cycle 4 Consolidation (LAL1913)
02
Targets
DNA polymerase familyPPAT (Amidophosphoribosyltransferase)DNA
Beyond the preview
Go deeper on Cycle 4 Consolidation-Gruppo Italiano Malattie EMatologiche dell'Adulto-acute lymphoblastic leukemia-lymphoblastic lymphoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cycle 4 Consolidation-Gruppo Italiano Malattie EMatologiche dell'Adulto-acute lymphoblastic leukemia-lymphoblastic lymphoma.